Molecular Cancer Therapeutics CTRC-AACR San Antonio Breast Cancer Symposium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jiang, X.
Right arrow Articles by Roberge, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jiang, X.
Right arrow Articles by Roberge, M.
Mol Cancer Ther. 2004;3:1221-1227
© 2004 American Association for Cancer Research

Inhibition of Chk1 by the G2 DNA damage checkpoint inhibitor isogranulatimide

Xiuxian Jiang1, Baoguang Zhao5, Robert Britton2,3, Lynette Y. Lim1, Dan Leong4, Jasbinder S. Sanghera4, Bin-Bing S. Zhou6, Edward Piers2, Raymond J. Andersen2,3 and Michel Roberge1

Departments of 1 Biochemistry and Molecular Biology, 2 Chemistry, and 3 Oceanography-Earth and Ocean Sciences, University of British Columbia, Vancouver, British Columbia, Canada; 4 Kinetek Pharmaceuticals Inc., Vancouver, British Columbia, Canada; and 5 Department of Structural Biology and 6 Oncology Research, GlaxoSmithKline, King of Prussia, Pennsylvania

Requests for reprints: Michel Roberge, 2146 Health Sciences Mall, Vancouver, British Columbia, Canada V6T 1Z3. Phone: 604-822-2304; Fax: 604-822-5227. E-mail: michelr{at}interchange.ubc.ca


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results and Discussion
 References
 
Inhibitors of the G2 DNA damage checkpoint can selectively sensitize cancer cells with mutated p53 to killing by DNA-damaging agents. Isogranulatimide is a G2 checkpoint inhibitor containing a unique indole/maleimide/imidazole skeleton identified in a phenotypic cell-based screen; however, the mechanism of action of isogranulatimide is unknown. Using natural and synthetic isogranulatimide analogues, we show that the imide nitrogen and a basic nitrogen at position 14 or 15 in the imidazole ring are important for checkpoint inhibition. Isogranulatimide shows structural resemblance to the aglycon of UCN-01, a potent bisindolemaleimide inhibitor of protein kinase Cß (IC50, 0.001 µmol/L) and of the checkpoint kinase Chk1 (IC50, 0.007 µmol/L). In vitro kinase assays show that isogranulatimide inhibits Chk1 (IC50, 0.1 µmol/L) but not protein kinase Cß. Of 13 additional protein kinases tested, isogranulatimide significantly inhibits only glycogen synthase kinase-3ß (IC50, 0.5 µmol/L). We determined the crystal structure of the Chk1 catalytic domain complexed with isogranulatimide. Like UCN-01, isogranulatimide binds in the ATP-binding pocket of Chk1 and hydrogen bonds with the backbone carbonyl oxygen of Glu85 and the amide nitrogen of Cys87. Unlike UCN-01, the basic N15 of isogranulatimide interacts with Glu17, causing a conformation change in the kinase glycine-rich loop that may contribute importantly to inhibition. The mechanism by which isogranulatimide inhibits Chk1 and its favorable kinase selectivity profile make it a promising candidate for modulating checkpoint responses in tumors for therapeutic benefit.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results and Discussion
 References
 
Normal cells respond to DNA damage by activating cell cycle checkpoints that delay the transition from G1 to S phase and from G2 to M phase while DNA is repaired (1). Most cancer cells have an inoperative G1 checkpoint due to inactivation of the p53 tumor suppressor gene but a functioning G2 checkpoint (2). It has been proposed that treatment with radiotherapy or DNA-damaging chemotherapeutic agents in combination with drugs that inhibit the G2 checkpoint might promote the selective killing of tumors bearing p53 mutations, thereby providing therapeutic benefit (3–9).

The G2 DNA damage checkpoint comprises signal transduction cascades that link the detection of DNA breaks to inhibition of entry into mitosis via inhibition of Cdk1 and to other DNA damage responses such as the induction of DNA repair and apoptosis. Several key players in this cascade are of relevance as potential drug targets. Upstream are ATM and ATR, two large protein kinases with homology to phosphatidylinositol-3 kinases that associate with damaged DNA (10). Downstream are the protein kinases Chk1 and Chk2 (11). They are substrates of ATM and ATR and can directly phosphorylate Cdc25C, reducing its ability to carry out its major function—to activate Cdk1 by cleaving inhibitory phosphates in the ATP-binding site of Cdk1.

The first G2 checkpoint inhibitors, caffeine and its derivative pentoxifylline, 2-aminopurine and 6-dimethylaminopurine, and staurosporine and its derivative UCN-01, were identified serendipitously (1). Subsequently, rational searches have been initiated using a cell-based assay and in vitro target-specific enzymatic assays. We have developed a 96-well phenotypic assay using human breast carcinoma MCF-7 cells in which p53 is inactivated via expression of a dominant-negative p53 mutant gene (12). The cells are arrested in G2 by ionizing radiation and treated with chemicals or crude natural extracts. Those that contain G2 checkpoint inhibitors force the G2-arrested cells to enter mitosis, where they are trapped in the presence of the antimicrotubule agent nocodazole. Mitotic cells are then quantified in a modified ELISA using the mitosis-specific antibody TG-3, which recognizes a Cdk1 phosphorylation site in nucleolin (13). This assay is not target specific and has revealed several checkpoint inhibitors, including isogranulatimide and granulatimide (Fig. 1), alkaloids containing a unique indole/maleimide/imidazole skeleton (12).



View larger version (16K):
[in this window]
[in a new window]
  		Figure 1. Structural formulas of isogranulatimide, granulatimide, and UCN-01.

 
UCN-01 (Fig. 1) may be considered the prototypical checkpoint inhibitor. It is the most potent of the G2 checkpoint inhibitors identified to date (14–16), is a potent inhibitor of Chk1 (17–19) and it is being tested in clinical trials for the treatment of cancer (20). This study was undertaken to elucidate the mechanism of action of isogranulatimide and to compare its properties to those of UCN-01.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results and Discussion
 References
 
Synthesis of Isogranulatimide Analogues
Granulatimide, isogranulatimide, isogranulatimides A to C, and 17-methylgranulatimide were synthesized and purified as described (12, 21). 10-Methylisogranulatimide was obtained in moderate yield by treatment of a solution of isogranulatimide in dimethylformamide with NaH followed by iodomethane. NMR spectroscopy confirmed that alkylation occurred at N10 and not N1.

G2 Checkpoint Assay
The ability of compounds to overcome G2 arrest caused by ionizing radiation in MCF-7 cells expressing a dominant-negative p53 gene was measured as described in ref. 12 using the mitosis-specific antibody TG-3 (22) and the enzyme-linked immunocytochemical assay procedure described in ref. 13. IC50 values for checkpoint inhibition were defined as the concentration causing half-maximal activity in this assay (12).

Protein Kinase Assays
Integrin-linked kinase 1, lymphocyte-specific kinase, mitogen-activated protein kinase kinase 1, Pim 1, p21-activated kinase 4, protein kinase Cß, protein kinase B{alpha}, and SRC were expressed as NH2-terminal glutathione S-transferase fusion proteins in Sf9 cells using the baculovirus expression system. Extracellular signal-regulated kinase 1 and glycogen synthase kinase-3ß were expressed as NH2-terminal glutathione S-transferase fusion proteins in Escherichia coli. The proteins were purified using glutathione-agarose beads. Purified extracellular signal-regulated kinase 1 was activated in vitro with active mitogen-activated protein kinase kinase 1. Cdk1 was isolated from mature seastar oocytes, casein kinase II from bovine brain, DNA-dependent protein kinase from activated HeLa cells, and protein kinase A from rat muscle using conventional column chromatography. Chk1 was purchased from Upstate Biotechnology, Inc. (Waltham, MA). Chk1 assays were carried out in a 25 µL volume containing 30 ng Chk1, 2.5 µg substrate peptide (KKKVSRSGLYRSPSMPENLNRPR), 15 mmol/L ß-glycerophosphate, 12 mmol/L 3-(N-morpholino)propanesulfonic acid (pH 7.4), 3 mmol/L EGTA, 1 mmol/L EDTA, 12 mmol/L MgCl2, 150 µmol/L DTT, 3 µmol/L ß-methyl aspartic acid, and 50 µmol/L {gamma}-[32P]ATP (~2,000 cpm/pmol) in the presence of compound diluted in 1% DMSO. The kinase reaction was initiated by the addition of ATP, carried out for 15 minutes at 22°C, and terminated by spotting 10 µL of the reaction volume onto a phosphocellulose Multiscreen plate (Millipore, Bedford, MA), which was washed extensively in 1% phosphoric acid. Scintillation fluid was added to the dried filter plate and radioactivity was quantitated in a Microbeta scintillation plate counter (Wallac, Gaithersburg, MD).

Other protein kinases were assayed as described in the following publications: extracellular signal-regulated kinase 1 (23), mitogen-activated protein kinase kinase 1 (24), casein kinase II (25), integrin-linked kinase 1 (26), Cdk1 (27), SRC (28), protein kinase B{alpha} (29), protein kinase Cß (30), Pim 1 (31), DNA-dependent protein kinase (32), lymphocyte-specific kinase (33), glycogen synthase kinase-3ß (34), protein kinase A (35), and p21-activated kinase 4 (36). For IC50 determination, assays were carried out using a series of compound concentrations covering the IC50 over at least 100-fold range. The inhibition values were plotted semilogarithmically against concentration. The IC50 values were obtained by regression analysis using the least squares method requiring a correlation factor of at least 0.95.

Crystallization and Data Collection
The Chk1 kinase domain was expressed, purified, and crystallized as described (37). The native Chk1 kinase domain was crystallized using 9% polyethylene glycol 8000, 0.2 mol/L ammonium sulfate, and 2% glycerol at neutral pH. To soak isogranulatimide into Chk1 crystals, isogranulatimide powder was added to Chk1 crystals in crystallization solution to obtain a saturated solution and incubated for 10 days at room temperature. X-ray data were collected using the Quantum-210 detector (Area Detector Systems Corporation, Poway, CA) at the Industrial Macromolecular Crystallography Association beam line 17-ID at the Advanced Photon Source in Argonne National Laboratory (Argonne, IL). Before X-ray data collection, the crystals were equilibrated into a cryoprotectant solution containing 11% polyethylene glycol 8000 and 20% glycerol and were flash frozen in a nitrogen cold stream at –180°C. The crystal belongs to the monoclinic P21 space group with cell dimensions a = 45.0 Å, b = 65.2 Å, c = 54.2 Å, and ß = 102.5° and contains one molecule per asymmetric unit. The crystal diffracted to 2.05 Å resolution. The structure was determined by difference Fourier as implemented in CNS program version 2000.1 (Molecular Simulation, Inc., San Diego, CA) using phases derived from the apo-Chk1 model (37). Fourier maps with coefficients 2|Fobs| – |Fcalc| and |Fobs| – |Fcalc| were used to fit the atomic model of the inhibitor by using the computer program O version 5.9 (Uppsala University, Uppsala, Sweden). Simulated annealing refinement followed by B-factor refinement were carried out by using the program CNX to a final Rfactor of 0.23 and Rfree of 0.26 at 2.05 Å resolution. The final model contains 2,224 protein atoms accounting for 276 of 289 amino acid residues of Chk1, 111 solvent atoms, and 21 inhibitor atoms.


   Results and Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
References
 
G2 Checkpoint Inhibition by Isogranulatimide: Importance of the Maleimide and Imidazole Rings
As a first step toward defining the mechanism of action of isogranulatimide, we determined the G2 checkpoint inhibitory activity of synthetic analogues, concentrating on the maleimide and imidazole rings, the functional groups of which are expected to contribute most to binding specificity through hydrogen bonding.

To assess the importance of the imide nitrogen, 10-methylisogranulatimide was prepared by alkylation of isogranulatimide and tested in the G2 checkpoint inhibition cell-based assay. It was ~15-fold less potent than isogranulatimide, showing activity only at concentrations >20 µmol/L (Fig. 2). Peak activity was observed at 200 µmol/L, compared with 10 µmol/L for isogranulatimide, followed by loss of checkpoint inhibition activity at higher concentrations, indicating that concentrations of 10-methylisogranulatimide >200 µmol/L are toxic to cells or inhibit the G2-M transition. This result suggests that the imide nitrogen participates in hydrogen bonding with its target and/or that an increase in bulk at that position interferes with binding to the target.



View larger version (24K):
[in this window]
[in a new window]
  		Figure 2. Checkpoint inhibitory activity of isogranulatimide, 10-methylisogranulatimide, and 9-hydroxyisogranulatimide. Sixteen hours after irradiation, G2-arrested cells were exposed to nocodazole and to different concentrations of the compounds for 8 hours. Checkpoint inhibition was determined by enzyme-linked immunocytochemical assay as described in Materials and Methods.

 
Isogranulatimide shows resemblance to the aglycon portion of UCN-01 (Fig. 1). However, isogranulatimide has a maleimide group, whereas UCN-01 bears a hydroxymaleimide. We next prepared 9-hydroxyisogranulatimide (Fig. 2) as an analogue with a hydroxymaleimide. Because UCN-01 inhibits the G2 checkpoint more potently than isogranulatimide (Table 1), we expected that the OH substitution would increase the checkpoint inhibitory activity of the analogue. However, 9-hydroxyisogranulatimide showed little checkpoint inhibitory activity at any concentration tested (Fig. 2). This may indicate a requirement for a carbonyl group at position 9 for activity. However, this compound was relatively unstable and we cannot rule out the possibility that the lack of activity could be due to compound decomposition during incubation with cells.


View this table:
[in this window]
[in a new window]
  		Table 1. In vitro protein kinase inhibition profile of isogranulatimide and analogues

 
Our efforts next concentrated on the imidazole ring of isogranulatimide. A second feature that distinguishes isogranulatimide from UCN-01 is a basic nitrogen in the imidazole ring, which has no counterpart in the substituted indole ring of UCN-01. The basic nitrogen's lone pair of electrons is not involved in the {pi} bonds that contribute to the aromaticity of isogranulatimide and is thus capable of engaging in hydrogen bonds to contribute to binding affinity and specificity. In addition, the imidazole pKa of 7.00 suggests the existence of positively charged isogranulatimide species in physiologic environments. We therefore investigated the importance of the position of the basic nitrogen in the imidazole.

The natural compound granulatimide exists as two tautomers, with a basic nitrogen at position 1 or 3, as indicated in Fig. 3. Granulatimide shows checkpoint inhibitory activity at low micromolar concentrations. We prepared isogranulatimide C, with a basic nitrogen at position 1 only and this compound also showed strong activity. We also synthesized isogranulatimide A, with a basic nitrogen at position 3 only (Fig. 3). This compound showed no significant activity, indicating that a basic nitrogen at position 1 is required. 17-Methylgranulatimide also has a basic nitrogen at position 3 only (Fig. 3) and this compound was also inactive (Fig. 3). Isogranulatimide and isogranulatimide B, with a basic nitrogen at position 2, both showed strong activity at low micromolar concentrations. This set of data indicates that a basic nitrogen at position 1 or 2 in the imidazole ring is necessary for G2 checkpoint inhibition and that the activity of granulatimide most likely resides in the tautomer bearing a basic nitrogen at position 1. Interestingly, although the four active compounds were roughly equipotent, a drop in activity was observed at supraoptimal concentrations of granulatimide and isogranulatimide B but not isogranulatimide and isogranulatimide C, indicating that high concentrations of the latter two are not cytotoxic or do not inhibit cell cycle progression (Fig. 3).



View larger version (28K):
[in this window]
[in a new window]
  		Figure 3. Checkpoint inhibitory activity of isogranulatimide analogues differing in the position of the basic nitrogen in the imidazole ring. Sixteen hours after irradiation, G2-arrested cells were exposed to nocodazole and to different concentrations of the compounds for 8 hours. Checkpoint inhibition was determined by enzyme-linked immunocytochemical assay as described in Materials and Methods. The two tautomeric forms of granulatimide are indicated. Double dots, nitrogen free electrons.

 
Inhibition of Chk1 by Isogranulatimide and Analogues
The structural resemblance of isogranulatimide to the aglycon of UCN-01, a potent inhibitor of the DNA damage response kinase Chk1, suggested that isogranulatimide might also inhibit this kinase. We therefore determined the effect of isogranulatimide and the three analogues that displayed checkpoint inhibitory activity on the protein kinase activity of Chk1 in vitro. As shown in Table 1, isogranulatimide potently inhibited Chk1. Granulatimide and isogranulatimide C were also potent Chk1 inhibitors, whereas isogranulatimide B was less potent. Given the important role of Chk1 in the G2 checkpoint response (38), it is likely that Chk1 inhibition contributes importantly to G2 checkpoint inhibition by isogranulatimide.

Selectivity of Isogranulatimide and Analogues toward Chk1
To evaluate the specificity of isogranulatimide and analogues, we tested their effect on the in vitro activity of 14 additional protein kinases and compared their inhibitory profiles with that of UCN-01 (Table 1). Isogranulatimide did not inhibit any of these kinases more potently than it inhibits Chk1; it inhibited glycogen synthase kinase-3ß somewhat less potently and showed weak activity toward Cdk1 and even weaker activity toward the 12 additional kinases tested, including protein kinase Cß. By contrast, UCN-01 was a more potent inhibitor of protein kinase Cß than of Chk1, as reported previously (17–19, 39), and a potent submicromolar inhibitor of Cdk1, glycogen synthase kinase-3ß, lymphocyte-specific kinase, p21-activated kinase 4, and protein kinase B{alpha}.

Granulatimide and isogranulatimide B and C showed a different kinase inhibition profile than isogranulatimide (Table 1). The profile of isogranulatimide C resembled that of isogranulatimide, except that isogranulatimide C is a 10 times less potent inhibitor of glycogen synthase kinase-3ß. The inhibitory profile of granulatimide also resembled that of isogranulatimide, except that granulatimide was a 20-fold more potent inhibitor of lymphocyte-specific kinase. Isogranulatimide B inhibited seven kinases more potently than isogranulatimide.

Overall, the specificities of isogranulatimide and UCN-01 are very different. Isogranulatimide is a less potent inhibitor of the G2 checkpoint and of Chk1 by 2 orders of magnitude but, judging from this kinase panel, it seems to be a more selective Chk1 inhibitor than UCN-01. Notably, isogranulatimide does not inhibit protein kinase Cß, whereas UCN-01 is a more potent inhibitor of protein kinase Cß than Chk1. Although isogranulatimide, granulatimide, and isogranulatimide B and C are equally potent checkpoint inhibitors and all inhibit Chk1 in vitro, isogranulatimide and isogranulatimide C seem the most selective toward Chk1, whereas granulatimide is less selective and isogranulatimide B shows no selectivity toward Chk1. Interestingly, the broader spectrum of kinase inhibition by granulatimide and isogranulatimide B parallels their lack of checkpoint inhibition at high concentration in the cell-based assay (Fig. 3), which may reflect inhibition of additional kinases required for the G2-M transition or for cell survival. Therefore, isogranulatimide and isogranulatimide C seem the most selective checkpoint inhibitors.

Crystal Structure of an Isogranulatimide-Chk1 Complex
To define the structural basis for inhibition of Chk1 by isogranulatimide, apo-Chk1 crystals were soaked with isogranulatimide and the structure of the complex was determined by X-ray crystallography as described in Materials and Methods. As shown in Fig. 4A, isogranulatimide binds in the ATP-binding pocket of Chk1, in one orientation only, with the imidazole facing toward the center of the ATP-binding pocket. The maleimide NH of isogranulatimide makes a hydrogen bond (3.0 Å) to the backbone carbonyl oxygen of Glu85, whereas the oxygen atom at position 9 of the maleimide accepts a hydrogen bond (2.8 Å) from the amide nitrogen of Cys87 in the linker region. The basic nitrogen at position 15 in the imidazole ring interacts with a carbonyl oxygen in the side chain of Glu17. One planar hydrophobic surface of isogranulatimide (top surface in Fig. 4A) makes many favorable van der Waals contacts with the backbone and side chains of residues from the NH2-terminal domain of Chk1, including Leu15, Val23, Ala36, Lys38, Leu84, and Tyr86. The opposite hydrophobic surface (bottom surface in Fig. 4A) makes van der Waals interactions with the side chains of Val68, Leu137, and Asp148 from both NH2- and COOH-terminal domains of Chk1.



View larger version (32K):
[in this window]
[in a new window]
  		Figure 4. Structural basis for Chk1 inhibition by isogranulatimide. A, binding of isogranulatimide in the active site of Chk1: Chk1 atoms involved in binding to isogranulatimide or to UCN-01 binding. Dashed lines, hydrogen bonds between isogranulatimide and Chk1 (in Å); gray, inhibitor carbons; beige, enzyme carbons; red, oxygens; blue, nitrogens. B, binding of UCN-01 in the active site of Chk1. C, conformation change in the Chk1 glycine-rich loop induced by isogranulatimide binding. Green, glycine-rich loop in the absence of isogranulatimide (IGR); blue, glycine-rich loop in the presence of isogranulatimide. Only the side chain of Glu17 is displayed.

 
For comparison, the crystal structure of the Chk1-UCN-01 complex (37) is shown in Fig. 4B. The two inhibitors form similar hydrogen bonds with the backbone carbonyl oxygen of Glu85 and the amide nitrogen of Cys87. Unlike isogranulatimide, UCN-01 also interacts with Ser147 through its hydroxyl group and with Glu91 and Glu134 through its tetrahydropyran ring. In the Chk1-UCN-01 complex, the side chain of Tyr20 bends inward toward the inhibitor molecule, whereas in the Chk1-isogranulatimide complex the side chain of Tyr20 turns away from the active site (see Fig. 4A and B).

Interestingly, the isogranulatimide-Chk1 complex differs significantly from the structures of the native Chk1 and of the UCN-01-Chk1 complex with respect to Glu17, which is in the enzyme's glycine-rich loop. In native Chk1 and in the Chk1-UCN-01 complex, the side chain of Glu17 points away from the enzyme active site, whereas in the isogranulatimide-Chk1 complex the Glu17 side chain points toward isogranulatimide and interacts with the basic N15 of the inhibitor. Glu17 is flanked on both sides by glycine residues, making this segment of the protein flexible. The conformational change in the glycine-rich loop caused by isogranulatimide binding is illustrated in Fig. 4C. The Chk1-isogranulatimide and Chk1-UCN-01 complexes also differ from each other in the side chain conformations of residues Glu91, Phe93, Glu134, Ser147, and Asp148. In addition, compared with the Chk1-UCN-01 binary complex, isogranulatimide is shifted slightly (by ~0.5 Å) outward from the pocket to avoid close contact between the maleimide carbonyl oxygen and the side chain of Leu84.

This crystal structure helps interpret the isogranulatimide structure-activity profile observed in our cell-based G2 checkpoint inhibition assay. The maleimide NH and the maleimide C9 carbonyl are necessary for activity and they are both involved in hydrogen bonding with Chk1. The interaction between the basic N15 of isogranulatimide and Glu17 explains why isogranulatimide binds Chk1 with a single mode—this interaction would not occur if the indole were in the position of the imidazole, and binding affinity would be considerably reduced. The crystal structure may also explain the role of the basic N15 in isogranulatimide in checkpoint inhibition. Because imidazole has a pKa of 7.00, it is possible that N15 bears a positive charge in the complex that adds to the strength of the hydrogen bond with the negatively charged carboxylate of Glu17. Given the general importance of the glycine-rich loop in the binding of ATP and substrate to kinases (40), isogranulatimide may inhibit Chk1 both by directly competing with ATP and by hindering interaction with substrate proteins. The structure may also reveal why 9-hydroxyisogranulatimide is not more active than isogranulatimide as a checkpoint inhibitor: the unique orientation of isogranulatimide in the ATP-binding site, with the imidazole facing toward the center of the ATP-binding pocket, puts the hydroxyl group at position 9 on the side of the maleimide ring where it cannot interact with Ser147.

This study defines the structural elements of isogranulatimide required for activity as a G2 checkpoint inhibitor and a Chk1 kinase inhibitor. Current evidence indicates that Chk1 activity is required for the G2 checkpoint, whereas Chk2 plays a smaller supportive role (38). It is likely that the most significant checkpoint target of isogranulatimide is Chk1 because it is a 40-fold less potent inhibitor of Chk2 than Chk1 and it does not inhibit ATM or ATR,7 although the involvement of other unidentified targets cannot be excluded. The results also show that isogranulatimide is a less potent but more selective kinase inhibitor than UCN-01, making it a promising candidate for modulating checkpoint responses in tumors for therapeutic benefit. This study also shows that a suitably designed phenotypic assay can be a powerful drug discovery tool to identify chemicals with pharmacologically desirable properties, such as cell permeability, stability in cellular environments, and suitable selectivity profile, which are difficult to design or to engineer into traditional in vitro target-specific enzymatic assays.


   Acknowledgments
 
We thank Hilary Anderson for comments on the article and Cecilia Chiu and Natalie Strynadka for help with the crystal structure figure.


   Footnotes
 
Grant support: National Cancer Institute of Canada (M. Roberge and R.J. Andersen) and Natural Sciences and Engineering Research Council (R.J. Andersen and E. Piers).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: B-B.S. Zhou is presently at Incyte Genomics, Inc., Stine-Haskell Research Center, 1090 Elkon Road, Newark, DE 19714.

7 Unpublished data. Back

Received 3/18/04; revised 7/21/04; accepted 8/11/04.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
 References
 

  1. Anderson HJ, Andersen RJ, Roberge M. Inhibitors of the G2 DNA damage checkpoint and their potential for cancer therapy. Prog Cell Cycle Res 2003;5:423–30.[Medline]
  2. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci U S A 1992;89:7491–5.[Abstract/Free Full Text]
  3. Walworth NC. Cell cycle checkpoint kinases: checking in on the cell cycle. Curr Opin Cell Biol 2000;12:697–704.[CrossRef][Medline]
  4. Hartwell L, Kastan MB. Cell cycle control and cancer. Science 1994;266:1821–8.[Abstract/Free Full Text]
  5. O'Connor PM. Cell cycle checkpoints: targets for anticancer therapy. Anticancer Drugs 1996;7:135–41.
  6. Fojo T. Cancer, DNA repair mechanisms, and resistance to chemotherapy. J Natl Cancer Inst 2001;93:1434–6.[Free Full Text]
  7. Sampath D, Plunkett W. Design of new anticancer therapies targeting cell cycle checkpoint pathways. Curr Opin Oncol 2001;13:484–90.[CrossRef][Medline]
  8. Shapiro GI, Harper JW. Anticancer drug targets: cell cycle and checkpoint control. J Clin Invest 1999;104:1645–53.[Medline]
  9. Flatt P, Pietenpol J. Mechanisms of cell-cycle checkpoints: at the crossroads of carcinogenesis and drug discovery. Drug Metab Rev 2000;32:283–305.[CrossRef][Medline]
  10. Goodarzi AA, Block WD, Lees-Miller SP. The role of ATM and ATR in DNA damage-induced cell cycle control. Prog Cell Cycle Res 2003;5:393–411.[Medline]
  11. Zhou BB, Sausville EA. Drug discovery targeting Chk1 and Chk2 kinases. Prog Cell Cycle Res 2003;5:413–21.[Medline]
  12. Roberge M, Berlinck RGS, Xu L, et al. High-throughput assay for G2 checkpoint inhibitors and identification of the structurally novel compound isogranulatimide. Cancer Res 1998;58:5701–6.[Abstract/Free Full Text]
  13. Roberge M, Cinel B, Anderson HJ, et al. Cell-based screen for antimitotic agents and identification of analogues of rhizoxin, eleutherobin and paclitaxel in natural extracts. Cancer Res 2000;60:5052–8.[Abstract/Free Full Text]
  14. Wang Q, Fan S, Eastman A, et al. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst 1996;88:956–65.[Abstract/Free Full Text]
  15. Yu L, Orlandi L, Wang P, et al. UCN-01 abrogates G2 arrest through a cdk2-dependent pathway that involves inactivation of the Wee1hu kinase. J Biol Chem 1998;273:33455–64.[Abstract/Free Full Text]
  16. Bunch RT, Eastman A. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. Clin Cancer Res 1996;2:791–7.[Abstract]
  17. Graves PR, Yu L, Schwarz JK, et al. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 2000;275:5600–5.[Abstract/Free Full Text]
  18. Busby EC, Leistritz DF, Abraham RT, Karnitz LM, Sarkaria JN. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res 2000;60:2108–12.[Abstract/Free Full Text]
  19. Jackson JR, Gilmartin A, Imburgia C, et al. An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage. Cancer Res 2000;60:566–72.[Abstract/Free Full Text]
  20. Sausville EA, Arbuck SG, Messmann R, et al. Phase I trial of 72-hour continuous infusion UCN-01 (7-hydroxystaurosporine) in patients with refractory neoplasms. J Clin Oncol 2001;19:2319–33.[Abstract/Free Full Text]
  21. Piers E, Britton R, Andersen RJ. Improved synthesis of isogranulatimide, a G2 checkpoint inhibitor. Syntheses of didemnimide C, isodidemnimide A, neodidemnimide A, 17-methylgranulatimide, and isogranulatimides A-C. J Org Chem 2000;65:530–5.[CrossRef][Medline]
  22. Anderson HJ, deJong G, Vincent I, Roberge M. Flow cytometry of mitotic cells. Exp Cell Res 1998;238:498–502.[CrossRef][Medline]
  23. Robbins DJ, Zhen E, Owaki H, et al. Regulation and properties of extracellular signal-regulated protein kinases 1 and 2 in vitro. J Biol Chem 1993;268:5097–106.[Abstract/Free Full Text]
  24. Zheng CF, Guan KL. Cloning and characterization of two distinct human extracellular signal-regulated kinase activator kinases, MEK1 and MEK2. J Biol Chem 1993;268:11435–9.[Abstract/Free Full Text]
  25. Charlton LA, Sanghera JS, Clark-Lewis I, Pelech SL. Structure-function analysis of casein kinase 2 with synthetic peptides and anti-peptide antibodies. J Biol Chem 1992;267:8840–5.[Abstract/Free Full Text]
  26. Persad S, Attwell S, Gray V, et al. Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase: critical roles for kinase activity and amino acids arginine 211 and serine 34. J Biol Chem 2001;276:27462–9.[Abstract/Free Full Text]
  27. Morrison DL, Sanghera JS, Stewart J, et al. Phosphorylation and activation of smooth muscle myosin light chain kinase by MAP kinase and cyclin-dependent kinase-1. Biochem Cell Biol 1996;74:549–57.[Medline]
  28. Cartwright CA, Kamps MP, Meisler AI, Pipas JM, Eckhart W. pp60c-src activation in human colon carcinoma. J Clin Invest 1989;83:2025–33.
  29. Paz K, Liu YF, Shorer H, et al. Phosphorylation of insulin receptor substrate-1 (IRS-1) by protein kinase B positively regulates IRS-1 function. J Biol Chem 1999;274:28816–22.[Abstract/Free Full Text]
  30. Bazzi MD, Nelsestuen GL. Role of substrate in determining the phospholipid specificity of protein kinase C activation. Biochemistry 1987;26:5002–8.[CrossRef][Medline]
  31. Palaty CK, Clark-Lewis I, Leung D, Pelech SL. Phosphorylation site substrate specificity determinants for the Pim-1 protooncogene-encoded protein kinase. Biochem Cell Biol 1997;75:153–62.[CrossRef][Medline]
  32. Block WD, Merkle D, Meek K, Lees-Miller SP. Selective inhibition of the DNA-dependent protein kinase (DNA-PK) by the radiosensitizing agent caffeine. Nucleic Acids Res 2004;32:1967–72.[Abstract/Free Full Text]
  33. Watts JD, Wilson GM, Ettenhadieh E, et al. Purification and initial characterization of the lymphocyte-specific protein-tyrosyl kinase p56lck from a baculovirus expression system. J Biol Chem 1992;267:901–7.[Abstract/Free Full Text]
  34. Thomas GM, Frame S, Goedert M, et al. A GSK3-binding peptide from FRAT1 selectively inhibits the GSK3-catalyzed phosphorylation of axin and ß-catenin. FEBS Lett 1999;458:247–51.[CrossRef][Medline]
  35. Machu TK, Olsen RW, Browning MD. Ethanol has no effect on cAMP-dependent protein kinase-, protein kinase C-, or Ca(2+)-calmodulin-dependent protein kinase II-stimulated phosphorylation of highly purified substrates in vitro. Alcohol Clin Exp Res 1991;15:1040–4.[Medline]
  36. Tuazon PT, Chinwah M, Traugh JA. Autophosphorylation and protein kinase activity of p21-activated protein kinase {gamma}-PAK are differentially affected by magnesium and manganese. Biochemistry 1998;37:17024–9.[CrossRef][Medline]
  37. Zhao B, Bower MJ, McDevitt PJ, et al. Structural basis for Chk1 inhibition by UCN-01. J Biol Chem 2002;277:46609–15.[Abstract/Free Full Text]
  38. Dang LH, Bettegowda C, Agrawal N, et al. Targeting vascular and avascular compartments of tumors with C. novyi-NT and anti-microtubule agents. Cancer Biol Ther 2004;3:326–37.[Medline]
  39. Akinaga S, Gomi K, Morimoto M, Tamaoki T, Okabe M. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res 1991;51:4888–92.[Abstract/Free Full Text]
  40. Aimes RT, Hemmer W, Taylor ST. Serine-53 at the tip of the glycine-rich loop of cAMP-dependent protein kinase: role in catalysis, P-site specificity, and interaction with inhibitors. Biochemistry 2000;39:8325–32.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 Mol. Biol. CellHome page
S. Jamil, S. Mojtabavi, P. Hojabrpour, S. Cheah, and V. Duronio
An Essential Role for MCL-1 in ATR-mediated CHK1 Phosphorylation
Mol. Biol. Cell, August 1, 2008; 19(8): 3212 - 3220.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
C. M. Sturgeon, Z. A. Knight, K. M. Shokat, and M. Roberge
Effect of combined DNA repair inhibition and G2 checkpoint inhibition on cell cycle progression after DNA damage.
Mol. Cancer Ther., April 1, 2006; 5(4): 885 - 892.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jiang, X.
Right arrow Articles by Roberge, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jiang, X.
Right arrow Articles by Roberge, M.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online